At Twenty/Twenty we turn practical research into technologies that offer individuals more control over one of the most vital senses – their eyesight.
Our innovations accelerate positive outcomes by improving insights to treatment between office visits.
“What’s unique at Twenty/Twenty is getting patients involved in their own care. Nobody is more invested in their health than the patient themselves.”
Keeping the Focus on Patients
Our mandate is to turn practical research into technologies that directly solve patient needs.
That means ensuring our intuitive products and therapies reach the patient. Removing barriers to access is a key component, so wherever existing methods and technology do not meet our needs, we are inventing new approaches. Twenty/Twenty was conceived for an era that demands better problem solving, unique ways to collaborate, and the open exchange of knowledge.
“Any challenge we face today is simply an innovation waiting to be discovered tomorrow.”
We are developing highly
Advanced Technologies.
We’re using them to
Prevent & Halt vision loss.
Two World-Renowned Innovators
Twenty/Twenty Therapeutics is a joint venture between Verily Life Sciences, an Alphabet company, and Santen Pharmaceutical, a leading Japanese ophthalmology company.
Here, Santen’s global ophthalmology business platform unites with Verily’s developmental science expertise to create and commercialize unique devices that transform eye care.
It’s a partnership that offers the long-term vision and funding that major advances demand.
This commitment allows us to explore new approaches, rethink existing knowledge, and enlist new technologies to advance the work being done by medical professionals to treat eye conditions.